Evelo Biosciences, Inc.

OTC: EVLO · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0001694665Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 34

v0.1 · 5/100 weight · pillars only

↑ workforce scale, Piotroski F · ↓ market scale, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$114.5M

Employees

as of 2026-08-31

Market cap

$1.9k

as of 2026-08-31

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$114.5M-$114.5M2022

Operating income-$108.5M-$108.5M2022

Total assets$64.4M$64.4M2022

Liabilities$69.4M$69.4M2022

Equity-$5.0M-$5.0M2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Evelo Biosciences, Inc.’s financial profile?

Evelo Biosciences, Inc. earned -$114.5M in FY2022 net income.

Peers · Healthcare

Longport, Inc.——CanaQuest Medical Corp.——iBX Group, Inc.——Redwood Scientific Technologies, Inc.——Juva Life Inc.——Assure Holdings Corp.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOCraig R. Jalbert

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeOTC: EVLO

Employees66

IPO date2018-05-08

Latest filings

8-K2024-01-26 DEF 14A2023-12-12 8-K2023-12-04 8-K2023-11-21 10-Q2023-11-09 8-K2023-10-27 8-K2023-10-17 8-K2023-08-21

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.